Moi͏̈se, Pierre (contributor); … - 2007
than the �limited marketing rights provided during the transition periods by
TRIPS�
3
(Maskus, 1997). Under Article 12 of …
conducting clinical trials necessary for obtaining marketing authorisation.
7
The LFPPI is ambiguous on the
granting of term … exclusivity from the date of
marketing authorisation.
8
The US Trade Representative has repeatedly used the �issuance of …